2 weeks Ago By ABMN Staff
Rhumbline Advisers grew its holdings in MorphoSys AG ( NASDAQ:MOR – Free Report ) by 17.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,187 shares of the company’s stock after purchasing an additional 785 shares during the period.
Rhumbline Advisers’ holdings in MorphoSys were worth $94,000 as of its most recent SEC filing. A number of other institutional investors have also recently made changes to their positions in MOR. Kynam Capital Management LP bought a new position in MorphoSys in the 4th quarter worth $41,923,000.
Carlson Capital L P bought a new position in MorphoSys in the 1st quarter valued at $17,241,000. TD Asset Management Inc boosted its stake in shares of MorphoSys by 153.8% during the fourth quarter.
TD Asset Management Inc now owns 361,138 shares of the company’s stock valued at $3,575,000 after purchasing an additional 218,870 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of MorphoSys by 6.
5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 124,545 shares of the company’s stock valued at $2,267,000 after buying an additional 7,644 shares during the last quarter.
Finally, Henry James International Management Inc. increased its position in shares of MorphoSys by 105.8% in the 1st quarter.
Henry James International Management Inc. now owns 88,506 shares of the company’s stock valued at $1,605,000 after acquiring an additional 45,506 shares during the period. Hedge funds and other institutional investors own 18.
38% of the company’s stock. MorphoSys Price Performance MorphoSys stock opened at $18.96 on Tuesday.
The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of -5.45 and a beta of 1.
20. The company has a fifty day simple moving average of $18.88 and a 200-day simple moving average of $18.
46. MorphoSys AG has a 52-week low of $4.18 and a 52-week high of $19.
50. The company has a quick ratio of 1.38, a current ratio of 1.
38 and a debt-to-equity ratio of 4.98. MorphoSys Profile MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States.
The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. See Also Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter .
.
